Navigation Links
Par Pharmaceutical Reports First Quarter 2008 Results
Date:5/8/2008

trategy, and I am pleased with our progress thus far. Par should be measured in large part by the achievement of certain accomplishments and milestones that position the Company for growth in 2009 and beyond."

In January, Strativa acquired the U.S. commercialization rights to Alfacell Corporation's Phase III product, ONCONASE, for an initial payment of $5 million. Results from the Phase IIIb clinical trial will be reported by mid-year. Subject to a complete review of the study results and discussions with the FDA, it is anticipated that an NDA could be filed as early as year-end 2008.

In March, Par commenced bioequivalence studies for Zensana(TM) (ondansetron) oral spray. Subject to favorable results and discussions with the FDA, it is expected that Strativa could file an NDA around the end of 2008.

In April, Strativa announced that its development partner, BioAlliance Pharma, reported positive preliminary, top-line results from a Phase III study of Loramyc(R) (miconazole Lauriad(R)). Subject to a complete review of the study results and discussions with the FDA, it is anticipated that an NDA could be filed by year-end 2008.

On May 7, 2008, Par announced that it amended its agreement with Spectrum Pharmaceuticals and paid $20 million in cash to increase its share of profits from the generic versions of GlaxoSmithKline's Imitrex(R) Injection, which will be immediately accretive to 2008 earnings. As a result of the agreement, Par's profit share shall increase from 38% to 95% from the commercialization of sumatriptan injection. Par will be permitted to sell generic versions of certain sumatriptan injection products with an expected launch date no later than November 2008. According to IMS Health, annual U.S. sales of Imitrex(R) are approximately $220 million.

2008 Financial Guidance

The Company's projections are based on its results for the first three months of 2008, as well as management's estimates regarding the impact of pr
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Vion Pharmaceuticals to Appeal Nasdaq Delisting
2. Amneal Pharmaceuticals Receives US FDA Approval for Three Generic Prescription Drugs; Two Using New FDA Electronic Filing Format
3. AMDL Signs Letter of Intent to Purchase a China Based Pharmaceutical Distribution Company
4. Par Pharmaceutical Acquires Spectrum Pharmaceuticals Interest In Sumatriptan Injection
5. ISTA Pharmaceuticals to Present at the Bank of America 2008 Health Care Conference
6. Cadient Group Continues Winning Streak; Receives Multiple Honors at 2008 Pharmaceutical Advertising and Marketing Excellence Awards
7. Alseres Pharmaceuticals, Inc. to Present at The Neurotech Industry Investing & Partnering Conference
8. Par Pharmaceutical to Host First Quarter 2008 Earnings Conference Call on May 9 at 9:00 AM
9. ADVENTRX Pharmaceuticals to Report First Quarter 2008 Results
10. BioCryst Pharmaceuticals to Announce First Quarter 2008 Financial Results on May 8, 2008
11. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... study finds a wide range of epigenetic changesalterations in ... environmental exposuresin children with Crohn,s disease (CD), reports ... Crohn,s & Colitis Foundation of America (CCFA). The ... a part of Wolters Kluwer Health . ... in several regions of the genome in children with CD, ...
(Date:8/22/2014)... Women treated for the cancer Hodgkin lymphoma will be ... after researchers estimated their risk of premature menopause with ... Journal of the National Cancer Institute , are ... women in England and Wales treated for the cancer ... Previous research has suggested that women with Hodgkin lymphoma ...
(Date:8/22/2014)... The New Jersey Institute for Food, Nutrition ... of New Jersey has joined forces with ChopChop ... young people about health and nutrition in a new ... organizations. , The partnership will encompass quarterly custom editions ... video communications. ChopChop Magazine features plenty of child-friendly ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Ticket Down ... in East Hartford, CT at Rentschler Field. There has never ... the United States than right now. After the strong showing at ... fans and the sport is being featured in large stadiums around ... an eight team tournament that featured some of the best club ...
(Date:8/22/2014)... Statesville, N.C. (PRWEB) August 22, 2014 ... the managed employee reward and recognition industry, has received ... With an extraordinary growth rate of 134%, TharpeRobbins remains ... companies in North America. TharpeRobbins was previously on the ... are honored to be included in this distinguished list ...
Breaking Medicine News(10 mins):Health News:Study shows epigenetic changes in children with Crohn's disease 2Health News:Scientists map risk of premature menopause after cancer treatment 2Health News:New Jersey Institute for Food, Nutrition & Health to Launch Innovative Partnership with Award-Winning Children’s Anti-Obesity Organization, ChopChop Kids 2Health News:New Jersey Institute for Food, Nutrition & Health to Launch Innovative Partnership with Award-Winning Children’s Anti-Obesity Organization, ChopChop Kids 3Health News:USA vs. Ecuador Tickets: Ticket Down Slashes USA (USMT) vs. Ecuador Tickets at Rentschler Field in East Hartford on Oct. 10th 2Health News:USA vs. Ecuador Tickets: Ticket Down Slashes USA (USMT) vs. Ecuador Tickets at Rentschler Field in East Hartford on Oct. 10th 3Health News:For The Fourth Time - TharpeRobbins Earns A Place On Prestigious Inc. Magazine 500|5000 List 2Health News:For The Fourth Time - TharpeRobbins Earns A Place On Prestigious Inc. Magazine 500|5000 List 3
... KUNMING, China, Sept. 13 /Xinhua-PRNewswire-FirstCall/ -- China,Shenghuo ... KUN ), which is engaged in ... nutritional supplement and cosmetic,products in the People,s ... the full-scale launch of its 12Ways(R) Chinese ...
... Sept. 13 Scimitar Equity Research, Inc.,(Scimitar) today ... Bulletin,Board: ABOS) entitled: "Enhancing the Recovery of Patients ... research review is,available on Scimitar,s website: http://www.scimitarequity.com ... Device The SEPET(TM) Liver Assist Device is ...
... correlation, with risk doubling as blood cells decline , ... declining blood platelet counts may be at increased risk ... behavioral and motor skill problems, researchers report. , Researchers ... Johns Hopkins University School of Medicine in Baltimore studied ...
... (Sept. 10, 2007) -- For high-blood-pressure patients, preventing or ... risk of heart failure. The study is published in ... by physician-scientists at NewYork-Presbyterian Hospital/Weill Cornell Medical Center in ... all high-blood-pressure patients, or 12 million Americans, have LVH ...
... Health Corp. is the Distributor of the Popular Dietary Supplement ... ... Health Corp. is proud to,announce its retail presence has expanded again ... and Sweet Bay,Supermarkets. LipidShield Plus is the popular NATURAL breakthrough ...
... Reports Solid Progress on Child Survival, NEW YORK, Sept. ... below 10 million per year to 9.7 million,down from almost ... an historic moment," said UNICEF Executive Director Ann M.,Veneman. "Now ... for the,achievement of the Millennium Development Goals." Among these ...
Cached Medicine News:Health News:China Shenghuo Pharmaceutical Holdings, Inc. Begins Full-Scale Launch of 12Ways(R) Chinese Herbal Skin Care Product Line 2Health News:China Shenghuo Pharmaceutical Holdings, Inc. Begins Full-Scale Launch of 12Ways(R) Chinese Herbal Skin Care Product Line 3Health News:China Shenghuo Pharmaceutical Holdings, Inc. Begins Full-Scale Launch of 12Ways(R) Chinese Herbal Skin Care Product Line 4Health News:Arbios Systems, Inc's Q2/07 Analyst Review Issued by Scimitar Equity Research, Inc. 2Health News:Falling Platelet Counts May Signal HIV-Linked Dementia 2Health News:Preventing or reducing enlarged heart decreases risk of heart failure 2Health News:New Health Corp. Announces the Addition of Hannaford Bros., Kash N Karry and Sweet Bay Supermarkets to its Retail Outlets 2Health News:Child Deaths Fall Below 10 Million For First Time 2Health News:Child Deaths Fall Below 10 Million For First Time 3Health News:Child Deaths Fall Below 10 Million For First Time 4
(Date:8/21/2014)... 2014 Nektar Therapeutics (NASDAQ: ... positive results from its Phase 3 pivotal clinical ... recombinant factor VIII (rFVIII) treatment for hemophilia A ... its primary endpoint in reducing annualized bleed rates ... on-demand arm. Top-line results from the ...
(Date:8/21/2014)... The spinal column is one of the most delicate and ... from the brain through the column control many key functions ... here can be life altering, and leave the victim in ... body. Though back injury and disease can have an intensely ... available to make things better than ever before. Laser ...
(Date:8/21/2014)... 21, 2014 /CNW/ - Eisai Limited is pleased to support ... first-of-its-kind comic book available in Canada . ... specifically to educate children and their parents about epilepsy, the ... affecting more than 300,000 Canadians. Eisai is guided by a ... in which the patient is central – there was a ...
Breaking Medicine Technology:Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5Don't Live in Pain: Four Life Improving Benefits of Back Surgery 2Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2
... N.J., Feb. 3, 2011 BioNeutral Group, Inc. (OTC ... science technology-based company, today announced the formation of BioNeutral ... Inc., and the appointment of Frank Battafarano as the ... BioNeutral Services will market and distribute a ...
... 2011 A VANIR Pharmaceuticals, Inc. ... the three months ended December 31, 2010. For the ... $12.1 million, or $0.11 loss per share, compared with a net ... same period in fiscal 2010. Net revenues consisting primarily of royalty ...
Cached Medicine Technology:BioNeutral Group Announces the Formation of Kentucky-Based BioNeutral Services, Inc. and the Appointment of Frank Battafarano as Chairman and CEO of BioNeutral Services, Inc. 2BioNeutral Group Announces the Formation of Kentucky-Based BioNeutral Services, Inc. and the Appointment of Frank Battafarano as Chairman and CEO of BioNeutral Services, Inc. 3AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results 2AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results 3AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results 4AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results 5AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results 6
Mounted on a remarkably lightweight and,flexible cotton headband with crown strap,the Sport is fully adjustable....
... putty is a product of AlloSource, ... in human tissue processing, and Interpore ... technology. InterGro combines AlloGro DBM ... to deliver a unique bone graft ...
... bone content (93% by volume) of any ... excellent handling characteristics, which will enhance any ... alone or as a graft extender for ... The high molecular weight biocompatible carrier allows ...
... DS Strep A is a qualitative assay for ... swabs. The ICON DS Strep A test excels ... rare and low positive colonization samples. This CLIA ... outstanding performance, ICON DS Strep A leaves little ...
Medicine Products: